Tag: Nonmerger

Displaying 1 - 20 of 360 results.

Pages

The Federal Trade Commission filed a complaint against the nation’s three largest dental supply companies alleging that they violated U.S. antitrust laws by conspiring to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners.
Recently, the Bureau of Economics published "Conditional Pricing Practices -- A Short Primer" as part of its Economic Issues series.
In an Initial Decision announced today, Chief Administrative Law Judge D. Michael Chappell upheld a Federal Trade Commission complaint against 1-800 Contacts, ruling that the agency has proved that the nation’s largest online retailer of contact lenses unlawfully orchestrated a web of...
The Federal Trade Commission has approved a sublicense submitted by Mallinckrodt ARD Inc. granting West Therapeutic Development, LLC certain rights to develop and market the specialty drug Synacthen Depot in the United States.Synacthen Depot contains a synthetic version of adrenocorticotropic...
Following a public comment period, the Federal Trade Commission has approved a final order and consent agreement in which the American Guild of Organists agreed to eliminate rules that restrict its members from competing for opportunities to perform.
The American Guild of Organists has agreed to eliminate rules that restrict its members from competing for opportunities to perform.The agreement between the FTC and the American Guild of Organists resolves a complaint by the agency alleging that the guild’s rules restrained competition and harmed...
The American Guild of Organists agreed to eliminate rules that restrict its members from competing for opportunities to perform to settle charges that the guild’s rules restrained competition and harmed consumers in violation of the FTC Act. The guild represents approximately 15,000...
On January 18, 2017, the Commission settled its recent challenge to the 2013 acquisition by Questcor Pharmaceuticals, Inc. (subsequently acquired by Mallinckrodt plc) of rights to the drug Synacthen from Novartis AG.
The FTC filed a complaint in federal district court charging Shire ViroPharma Inc. with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl Capsules. The complaint alleges that to maintain its...
The FTC's complaint alleges that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Lidoderm.  The agreement not to market an authorized generic – often...
With some exceptions, Section 8 of the Clayton Act prohibits the same individual from serving as an officer or director of two competing corporations. Like other portions of the forward-looking Clayton Act (including Section 7 with its proscription on mergers that are likely to harm...
The FTC's administrative complaint against Impax charges that in 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013. In exchange, Endo paid Impax more than $112 million.Endo...
OFTACOOP, a Puerto Rico ophthalmologist cooperative, has agreed to settle FTC charges that its actions harmed competition.  The complaint charges that  OFTACOOP – also known as Cooperativa de Médico Oftalmólogos de Puerto Rico –  unlawfully orchestrated an agreement among competing...

Pages